Site icon Healthcare, Lifestyle, Entertainment, Living and Travel

Regeneron’s cancer therapy gets EU approval (NASDAQ:REGN)


Regeneron Pharmaceuticals (NASDAQ:REGN) mentioned on Monday its bispecific antibody Ordspono (odronextamab) has been cleared by the European Commission for the remedy of relapsed/refractory follicular lymphoma and diffuse giant b-cell lymphoma, after two or extra traces of systemic therapy.

Ordspono isREGN



Source: Seekingalpha

Exit mobile version